门诊股总动脉支架置入治疗闭塞性疾病的短期、中期和长期结果
该研究回顾性分析了296例患者共349处股总动脉病变,在门诊血管造影室由12名血管外科医生行支架置入术。结果显示primary-assisted patency达95.7%,secondary patency达99.1%,30天不良事件率3.7%,肢体丧失率4.3%,75个月生存率70%。结论认为股总动脉支架置入安全有效,可作为特定病例中动脉内膜剥脱术的替代方案。
要点
- 股总动脉支架置入的primary-assisted patency为95.7%,secondary patency为99.1%,长期通畅性可接受。
- 30天不良事件率3.7%,长期并发症少见,安全性优于股动脉内膜剥脱术。
- 溃疡/坏疽患者primary patency丢失风险是间歇性跛行者的1.8倍,肢体丧失风险高9.5倍。
核心结论
- 股总动脉支架置入安全有效,primary-assisted和secondary patency持久,可作为特定病例中动脉内膜剥脱术的替代方案。
研究设计与样本
- 回顾性研究,纳入2012至2021年在门诊血管造影室由12名血管外科医生治疗的296例患者共349处股总动脉病变。
- 患者均为ASA III或IV级、Rutherford 3级及以上,平均年龄71岁,女性139例(47%),男性157例(53%)。
- 平均随访22个月(范围0-96个月),主要终点为免于再干预的支架通畅率。
主要发现
- Primary patency为72.5%,primary-assisted patency为95.7%,secondary patency为99.1%。
- 12条肢体(3.9%)发生支架内血栓形成,其中4条无法血运重建。
- 30天内不良事件13例(3.7%);30天后长期并发症包括2例支架血栓、2例假性动脉瘤、1例支架夹层、1例支架移位、1例血肿。
- 349条治疗肢体中肢体丧失率为4.3%,其中膝下截肢7例、膝上截肢8例;75个月时生存率为70%。
- 既往心肌梗死与primary patency丢失相关(P = .002);溃疡/坏疽患者较间歇性跛行患者primary patency丢失风险高1.8倍(P = .035),肢体丧失风险高9.5倍(P = .045);静息痛患者肢体丧失风险高4.9倍(P = .007)。
临床怎么用
- 对于ASA III-IV级、Rutherford 3级及以上的股总动脉闭塞性疾病患者,支架置入可作为动脉内膜剥脱术的替代选择。
- 溃疡/坏疽或静息痛患者支架置入后肢体丧失风险显著增高,需加强术后监测和随访。
- 既往心肌梗死患者primary patency丢失风险增加,应纳入更密切的通畅性监测计划。
局限性
- 回顾性研究设计,非随机对照,存在选择偏倚可能。
- 平均随访22个月,部分患者随访时间较短,长期结果需进一步验证。
- 单中心门诊血管造影室经验,结果外推至其他机构需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Stenting of the common femoral artery (CFA) remains controversial despite advancements in technology and technique. We report on an updated and expanded list of patients previously shown to demonstrate the safety and efficacy of CFA stents. METHODS: We retrospectively reviewed data from 296 unique patients with 349 CFA lesions treated with endovascular CFA stents performed by 12 vascular surgeons in an outpatient office-based angiosuite from 2012 to 2021. All patients were American Society of Anesthesiologists class III or IV and Rutherford class 3 or higher. Patients were 139 women (47%) and 157 men (53%) with an average age of 71 years at the time of intervention. Surgical indications included claudication (42%), rest pain (42%), and ulcer or gangrene (16%). Common comorbidities were hypertension (89%), hyperlipidemia (69%), diabetes mellitus (46%), and hemodialysis (16%). Patency outcomes were measured by ankle-brachial index readings and duplex ultrasound examinations at 1 week, 3 months, 6 months, and every 6 months thereafter. The average length of follow-up was 22 months (range, 0-96 months). Our primary end point was stent patency free from reintervention. Safety outcomes were measured within 24 hours and again at 30 days. Postoperative complications were defined as events requiring transfer to hospital, extra treatment, and/or extra observation. Kaplan-Meier curves were used to evaluate patency outcomes. Cox proportional hazard regression models were used to determine correlation between outcomes and comorbidities. RESULTS: Primary patency was 72.5% and primary-assisted patency was 95.7%. Twelve limbs (3.9%) thrombosed with four limbs unable to be revascularized, achieving a secondary patency of 99.1%. There were 13 (3.7%) adverse events within 30 days. Long-term complications included two stent thromboses, two pseudoaneurysms, one stent dissection, one stent migration, and one hematoma >30 days after the procedure. Limb loss was 4.3% with 7 below-knee amputations and 8 above-knee amputations out of the 349 treated limbs. Previous myocardial infarction correlated with loss of primary patency (P = .002). Patients with ulcer/gangrene were 1.8 times more likely to lose primary patency compared with those with claudication (P = .035). Patients with ulcer/gangrene (P = .045) and rest pain (P = .007) compared with patients with claudication were 9.5 times and 4.9 times more likely to have limb loss, respectively. Survival was 70% at ≤75 months. CONCLUSIONS: Our results show that CFA stenting is safe and effective and provides durable long-term primary-assisted and secondary patency. Although primary patency for stenting is suboptimal, complication rates are notably lower than with femoral endarterectomy. The stenting also demonstrated long-term limb salvage, with only a 4.3% limb loss rate and an overall survival of 70.0% at 75 months. Thus, CFA stenting offers a suitable alternative to endarterectomy in select cases.
引用
- Schneider K, Lyon S, Jolicoeur W, et al. Outpatient common femoral artery stenting for occlusive disease: Short-, mid-, and long-term results. J Vasc Surg. 2026. PMID: 42229618. doi:10.1016/j.jvs.2026.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。